P3 Health Partners (NASDAQ:PIII – Get Free Report) and Strata Skin Sciences (NASDAQ:SSKN – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, dividends, analyst recommendations and profitability.
Analyst Recommendations
This is a breakdown of current ratings for P3 Health Partners and Strata Skin Sciences, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| P3 Health Partners | 1 | 2 | 1 | 0 | 2.00 |
| Strata Skin Sciences | 1 | 0 | 0 | 0 | 1.00 |
P3 Health Partners currently has a consensus target price of $14.00, suggesting a potential upside of 20.74%. Given P3 Health Partners’ stronger consensus rating and higher possible upside, research analysts plainly believe P3 Health Partners is more favorable than Strata Skin Sciences.
Volatility and Risk
Profitability
This table compares P3 Health Partners and Strata Skin Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| P3 Health Partners | -8.57% | -302.33% | -19.99% |
| Strata Skin Sciences | -35.64% | -476.73% | -33.49% |
Valuation and Earnings
This table compares P3 Health Partners and Strata Skin Sciences”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| P3 Health Partners | $1.46 billion | 0.06 | -$147.95 million | ($38.60) | -0.30 |
| Strata Skin Sciences | $30.98 million | 0.03 | -$10.09 million | ($1.41) | -0.11 |
Strata Skin Sciences has lower revenue, but higher earnings than P3 Health Partners. P3 Health Partners is trading at a lower price-to-earnings ratio than Strata Skin Sciences, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
7.8% of P3 Health Partners shares are owned by institutional investors. Comparatively, 32.4% of Strata Skin Sciences shares are owned by institutional investors. 10.9% of P3 Health Partners shares are owned by company insiders. Comparatively, 40.9% of Strata Skin Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
P3 Health Partners beats Strata Skin Sciences on 9 of the 14 factors compared between the two stocks.
About P3 Health Partners
P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. P3 Health Partners Inc. was founded in 2020 and is based in Henderson, Nevada.
About Strata Skin Sciences
STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. The company products include XTRAC and Pharos excimer lasers, and VTRAC lamp systems for the treatment systems that are used for the treatment of psoriasis, vitiligo, and other skin conditions. It also offers TheraClear Acne Therapy System for the treatment of mild to moderate inflammatory, comedonal, and pustular acne. The company was formerly known as MELA Sciences, Inc and changed its name to STRATA Skin Sciences, Inc. in January 2016. STRATA Skin Sciences, Inc. was incorporated in 1989 and is based in Horsham, Pennsylvania.
Receive News & Ratings for P3 Health Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for P3 Health Partners and related companies with MarketBeat.com's FREE daily email newsletter.
